{"id":26115,"date":"2026-03-02T15:47:31","date_gmt":"2026-03-02T14:47:31","guid":{"rendered":"https:\/\/lluita.org\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/"},"modified":"2026-03-02T15:51:54","modified_gmt":"2026-03-02T14:51:54","slug":"una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral","status":"publish","type":"post","link":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/","title":{"rendered":"A new combination of two HIV drugs matches the efficacy of the classic triple antiretroviral therapy"},"content":{"rendered":"<div class=\"field field--name-field-titol-llarg field--type-text-long field--label-hidden field__item\">\n<div class=\"field field--name-field-titol-llarg field--type-text-long field--label-hidden field__item\">\n<p><strong>Having alternatives with fewer drugs may reduce cumulative lifetime exposure to medication and offers new options in cases of resistance or intolerance to integrase inhibitors.<\/strong><\/p>\n<\/div>\n<div class=\"field field--name-body field--type-text-with-summary field--label-hidden field__item\">\n<p>Just a few decades ago, aging with HIV was unthinkable. Today, with a life expectancy similar to that of the general population, the\u00a0<strong>new challenge is to minimize the impact of chronic treatment<\/strong>\u00a0while research continues to advance toward a cure. In this context, The Lancet HIV\u00a0<a href=\"https:\/\/doi.org\/10.1016\/S2352-3018(26)00033-0\" target=\"_blank\" rel=\"noopener\">publishes\u00a0<\/a>the results of an international phase 3 clinical trial demonstrating, for the first time, that a\u00a0<strong>combination of just two antiviral drugs<\/strong>\u00a0\u2014doravirine and islatravir\u2014 which do not belong to the integrase inhibitor family, can be\u00a0<strong>as effective and safe as the most commonly used triple therapy for initial treatment<\/strong>, which does include this family of drugs.<\/p>\n<p>The study, led by the University Hospital of Bonn and the company Merck, included the participation of Dr.\u00a0<a href=\"https:\/\/www.irsicaixa.es\/en\/roger-paredes\" target=\"_blank\" rel=\"noopener\">Roger Paredes<\/a>, Scientific Director of the <a href=\"https:\/\/lluita.org\/en\/?swcfpc=1\">Fight Infections Foundation<\/a>, principal investigator at <a href=\"https:\/\/www.irsicaixa.es\/en\" target=\"_blank\" rel=\"noopener\">IrsiCaixa<\/a> \u2014a center jointly promoted by the \u201cla Caixa\u201d Foundation and the Department of Health of the Government of Catalonia\u2014 and Head of the Infectious Diseases Department at <a href=\"https:\/\/www.germanstrias.org\/en\/\">Hospital Germans Trias i Pujol<\/a>. \u201c<em>This study\u00a0<strong>enables simpler therapeutic strategies<\/strong>, with fewer drugs but the same virological efficacy, and\u00a0<strong>also offers alternatives in cases of resistance<\/strong>\u00a0to integrase inhibitors<\/em>,\u201d highlights Paredes.<\/p>\n<h4>A trial involving 756 newly diagnosed individuals<\/h4>\n<p>The trial included 756 people with HIV who were starting their first treatment after diagnosis. Half received the combination of doravirine and islatravir, while the other half received a triple therapy based on bictegravir, emtricitabine, and tenofovir alafenamide, one of the standard regimens currently administered.<\/p>\n<p>After one year of follow-up, nearly 90% of participants in\u00a0<strong>both groups achieved undetectable viral load in the blood<\/strong>. A comparable\u00a0<strong>recovery of CD4 immune cells<\/strong>, typically damaged by HIV, was also observed. Moreover, the results remained consistent regardless of initial viral load, immune status, or the presence of resistance-associated mutations among participants. \u201c<em>The two-drug combination\u00a0<strong>has demonstrated robustness comparable to triple therapy across very diverse clinical profiles<\/strong><\/em>,\u201d Paredes emphasizes.<\/p>\n<h4>Less cumulative exposure and more therapeutic options<\/h4>\n<p>Currently, most recommended initial treatments include integrase inhibitors. Although some dual therapies already exist, they are also generally based on this drug family. Reducing the number of medications may help decrease cumulative lifetime exposure and potentially\u00a0<strong>minimize long-term adverse effects or interactions with other treatments<\/strong>. In addition, having options that do not rely on integrase inhibitors\u00a0<strong>broadens the therapeutic arsenal in cases of resistance or intolerance<\/strong>.<\/p>\n<p>The results also\u00a0<strong>support the future development of long-acting treatment strategies<\/strong>. \u201c<em>Islatravir is a highly potent compound with prolonged activity, which could facilitate, in the future, more spaced dosing schedules, such as a once-weekly pill or a subcutaneous injection every six months<\/em>,\u201d Paredes notes.<\/p>\n<p>Overall, the study consolidates the path toward simpler, more flexible, and more personalized HIV treatments, while maintaining the ability to control the virus safely and sustainably over time.<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Having alternatives with fewer drugs may reduce cumulative lifetime exposure to medication and offers new options in cases of resistance or intolerance to integrase inhibitors. Just a few decades ago, aging with HIV was unthinkable. Today, with a life expectancy similar to that of the general population, the\u00a0new challenge is to minimize the impact of [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":26111,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[272],"class_list":["post-26115","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-vih-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>A new combination of two HIV drugs matches the efficacy of the classic triple antiretroviral therapy - Fundaci\u00f3 Lluita contra les Infeccions<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A new combination of two HIV drugs matches the efficacy of the classic triple antiretroviral therapy\" \/>\n<meta property=\"og:description\" content=\"Having alternatives with fewer drugs may reduce cumulative lifetime exposure to medication and offers new options in cases of resistance or intolerance to integrase inhibitors. Just a few decades ago, aging with HIV was unthinkable. Today, with a life expectancy similar to that of the general population, the\u00a0new challenge is to minimize the impact of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/\" \/>\n<meta property=\"og:site_name\" content=\"Fundaci\u00f3 Lluita contra les Infeccions\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T14:47:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-02T14:51:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lluita.org\/custom\/uploads\/2026\/03\/AdobeStock_140891313-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anna Carbonell\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anna Carbonell\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\\\/\"},\"author\":{\"name\":\"Anna Carbonell\",\"@id\":\"https:\\\/\\\/lluita.org\\\/#\\\/schema\\\/person\\\/9e839d213009b002d6f7c2ee1250fe7b\"},\"headline\":\"A new combination of two HIV drugs matches the efficacy of the classic triple antiretroviral therapy\",\"datePublished\":\"2026-03-02T14:47:31+00:00\",\"dateModified\":\"2026-03-02T14:51:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\\\/\"},\"wordCount\":499,\"image\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lluita.org\\\/custom\\\/uploads\\\/2026\\\/03\\\/AdobeStock_140891313-scaled.jpeg\",\"articleSection\":[\"VIH\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\\\/\",\"url\":\"https:\\\/\\\/lluita.org\\\/en\\\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\\\/\",\"name\":\"A new combination of two HIV drugs matches the efficacy of the classic triple antiretroviral therapy - Fundaci\u00f3 Lluita contra les Infeccions\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lluita.org\\\/custom\\\/uploads\\\/2026\\\/03\\\/AdobeStock_140891313-scaled.jpeg\",\"datePublished\":\"2026-03-02T14:47:31+00:00\",\"dateModified\":\"2026-03-02T14:51:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/#\\\/schema\\\/person\\\/9e839d213009b002d6f7c2ee1250fe7b\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lluita.org\\\/en\\\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lluita.org\\\/custom\\\/uploads\\\/2026\\\/03\\\/AdobeStock_140891313-scaled.jpeg\",\"contentUrl\":\"https:\\\/\\\/lluita.org\\\/custom\\\/uploads\\\/2026\\\/03\\\/AdobeStock_140891313-scaled.jpeg\",\"width\":2560,\"height\":1707,\"caption\":\"Senior man taking pills, closeup\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lluita.org\\\/en\\\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\\\/\\\/lluita.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A new combination of two HIV drugs matches the efficacy of the classic triple antiretroviral therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lluita.org\\\/#website\",\"url\":\"https:\\\/\\\/lluita.org\\\/\",\"name\":\"Fundaci\u00f3 Lluita contra les Infeccions\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lluita.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lluita.org\\\/#\\\/schema\\\/person\\\/9e839d213009b002d6f7c2ee1250fe7b\",\"name\":\"Anna Carbonell\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9637245f0044f4f4aedd08788b249921759104fca83e558cdc47e0145161744b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9637245f0044f4f4aedd08788b249921759104fca83e558cdc47e0145161744b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9637245f0044f4f4aedd08788b249921759104fca83e558cdc47e0145161744b?s=96&d=mm&r=g\",\"caption\":\"Anna Carbonell\"},\"url\":\"https:\\\/\\\/lluita.org\\\/en\\\/author\\\/acarbonell\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"A new combination of two HIV drugs matches the efficacy of the classic triple antiretroviral therapy - Fundaci\u00f3 Lluita contra les Infeccions","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/","og_locale":"en_US","og_type":"article","og_title":"A new combination of two HIV drugs matches the efficacy of the classic triple antiretroviral therapy","og_description":"Having alternatives with fewer drugs may reduce cumulative lifetime exposure to medication and offers new options in cases of resistance or intolerance to integrase inhibitors. Just a few decades ago, aging with HIV was unthinkable. Today, with a life expectancy similar to that of the general population, the\u00a0new challenge is to minimize the impact of [&hellip;]","og_url":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/","og_site_name":"Fundaci\u00f3 Lluita contra les Infeccions","article_published_time":"2026-03-02T14:47:31+00:00","article_modified_time":"2026-03-02T14:51:54+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/lluita.org\/custom\/uploads\/2026\/03\/AdobeStock_140891313-scaled.jpeg","type":"image\/jpeg"}],"author":"Anna Carbonell","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Anna Carbonell","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/#article","isPartOf":{"@id":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/"},"author":{"name":"Anna Carbonell","@id":"https:\/\/lluita.org\/#\/schema\/person\/9e839d213009b002d6f7c2ee1250fe7b"},"headline":"A new combination of two HIV drugs matches the efficacy of the classic triple antiretroviral therapy","datePublished":"2026-03-02T14:47:31+00:00","dateModified":"2026-03-02T14:51:54+00:00","mainEntityOfPage":{"@id":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/"},"wordCount":499,"image":{"@id":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/#primaryimage"},"thumbnailUrl":"https:\/\/lluita.org\/custom\/uploads\/2026\/03\/AdobeStock_140891313-scaled.jpeg","articleSection":["VIH"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/","url":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/","name":"A new combination of two HIV drugs matches the efficacy of the classic triple antiretroviral therapy - Fundaci\u00f3 Lluita contra les Infeccions","isPartOf":{"@id":"https:\/\/lluita.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/#primaryimage"},"image":{"@id":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/#primaryimage"},"thumbnailUrl":"https:\/\/lluita.org\/custom\/uploads\/2026\/03\/AdobeStock_140891313-scaled.jpeg","datePublished":"2026-03-02T14:47:31+00:00","dateModified":"2026-03-02T14:51:54+00:00","author":{"@id":"https:\/\/lluita.org\/#\/schema\/person\/9e839d213009b002d6f7c2ee1250fe7b"},"breadcrumb":{"@id":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/#primaryimage","url":"https:\/\/lluita.org\/custom\/uploads\/2026\/03\/AdobeStock_140891313-scaled.jpeg","contentUrl":"https:\/\/lluita.org\/custom\/uploads\/2026\/03\/AdobeStock_140891313-scaled.jpeg","width":2560,"height":1707,"caption":"Senior man taking pills, closeup"},{"@type":"BreadcrumbList","@id":"https:\/\/lluita.org\/en\/una-nova-combinacio-de-dos-farmacs-contra-el-vih-iguala-leficacia-de-la-classica-triple-terapia-antiretroviral\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/lluita.org\/en\/"},{"@type":"ListItem","position":2,"name":"A new combination of two HIV drugs matches the efficacy of the classic triple antiretroviral therapy"}]},{"@type":"WebSite","@id":"https:\/\/lluita.org\/#website","url":"https:\/\/lluita.org\/","name":"Fundaci\u00f3 Lluita contra les Infeccions","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lluita.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lluita.org\/#\/schema\/person\/9e839d213009b002d6f7c2ee1250fe7b","name":"Anna Carbonell","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9637245f0044f4f4aedd08788b249921759104fca83e558cdc47e0145161744b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9637245f0044f4f4aedd08788b249921759104fca83e558cdc47e0145161744b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9637245f0044f4f4aedd08788b249921759104fca83e558cdc47e0145161744b?s=96&d=mm&r=g","caption":"Anna Carbonell"},"url":"https:\/\/lluita.org\/en\/author\/acarbonell\/"}]}},"_links":{"self":[{"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/posts\/26115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/comments?post=26115"}],"version-history":[{"count":2,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/posts\/26115\/revisions"}],"predecessor-version":[{"id":26120,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/posts\/26115\/revisions\/26120"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/media\/26111"}],"wp:attachment":[{"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/media?parent=26115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lluita.org\/en\/wp-json\/wp\/v2\/categories?post=26115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}